Malaria vaccines: preferred product characteristics and clinical development considerations PDF Download

Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Malaria vaccines: preferred product characteristics and clinical development considerations PDF full book. Access full book title Malaria vaccines: preferred product characteristics and clinical development considerations by World Health Organization. Download full books in PDF and EPUB format.

Malaria vaccines: preferred product characteristics and clinical development considerations

Malaria vaccines: preferred product characteristics and clinical development considerations PDF Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240057463
Category : Medical
Languages : en
Pages : 77

Book Description
Preferred product characteristics” (PPCs) are key tools to incentivize and guide the development of urgently needed health products. The PPCs published here aim to articulate the public health need, preferred characteristics, and clinical development considerations for new malaria vaccines. WHO PPCs were initially conceived in 2012-2013 as a class of research-oriented normative guidance documents. The first edition of the WHO PPCs for malaria vaccines (WHO/IVB/14.09), published in 2014, was the first-in-class of these documents. The document published here is an update to the 2014 edition. Since the first malaria vaccine PPCs were published in 2014, major milestones in malaria vaccine R&D have been achieved. In 2021, RTS,S/AS01 became the first malaria vaccine to be recommended by WHO for use in moderate- to high-transmission settings in sub-Saharan Africa. However, a healthy market of vaccines will be needed to meet the global demand. A continued focus on developing new and improved vaccines will be vital in our efforts to reduce global malaria burden and to achieve elimination and eradication. This includes malaria vaccines to prevent blood-stage infection, reduce morbidity and mortality, and/or reduce community-level transmission.

Malaria vaccines: preferred product characteristics and clinical development considerations

Malaria vaccines: preferred product characteristics and clinical development considerations PDF Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240057463
Category : Medical
Languages : en
Pages : 77

Book Description
Preferred product characteristics” (PPCs) are key tools to incentivize and guide the development of urgently needed health products. The PPCs published here aim to articulate the public health need, preferred characteristics, and clinical development considerations for new malaria vaccines. WHO PPCs were initially conceived in 2012-2013 as a class of research-oriented normative guidance documents. The first edition of the WHO PPCs for malaria vaccines (WHO/IVB/14.09), published in 2014, was the first-in-class of these documents. The document published here is an update to the 2014 edition. Since the first malaria vaccine PPCs were published in 2014, major milestones in malaria vaccine R&D have been achieved. In 2021, RTS,S/AS01 became the first malaria vaccine to be recommended by WHO for use in moderate- to high-transmission settings in sub-Saharan Africa. However, a healthy market of vaccines will be needed to meet the global demand. A continued focus on developing new and improved vaccines will be vital in our efforts to reduce global malaria burden and to achieve elimination and eradication. This includes malaria vaccines to prevent blood-stage infection, reduce morbidity and mortality, and/or reduce community-level transmission.

Monoclonal antibodies for malaria prevention: preferred product characteristics and clinical development considerations

Monoclonal antibodies for malaria prevention: preferred product characteristics and clinical development considerations PDF Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240070982
Category : Medical
Languages : en
Pages : 36

Book Description
Preferred product characteristics (PPCs) are key tools to incentivize and guide the development of urgently needed health products. The PPCs published here aim to articulate the public health need, preferred characteristics, and clinical development considerations for monoclonal antibodies (mAbs) for malaria prevention. Alongside the development of new malaria vaccines and chemoprevention drugs, there have been recent R&D advances in the development of mAbs for malaria prevention. Passive immunization with mAbs through direct administration of functional antibodies could potentially overcome some of the limitations of vaccines by providing immediate protection. Furthermore, mAbs with simplified dose regimens could potentially circumvent some of the coverage and adherence issues faced by malaria chemoprevention. To support this quickly developing R&D area, WHO convened a scientific development group to consider the PPCs for mAbs to be used for malaria prevention, with a focus on the reduction of morbidity and mortality in infants and children due to Plasmodium falciparum.

World malaria report 2022

World malaria report 2022 PDF Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240064893
Category : Medical
Languages : en
Pages : 372

Book Description
Each year, WHO’s World malaria report offers in-depth information on the latest trends in malaria control and elimination at global, regional and country levels. The report highlights progress towards global targets and describes opportunities and challenges for curbing and eliminating the disease. This year’s report includes three new sections on: (1) global and regional initiatives launched in 2021 and 2022; (2) global malaria surveillance and country-level case studies on surveillance systems assessments; and (3) research and development. The report also includes an expanded section on threats to malaria control, with a focus on the declining effectiveness of insecticide-treated mosquito nets.

Health technologies gaps and strengthening research and development systems

Health technologies gaps and strengthening research and development systems PDF Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240100997
Category : Medical
Languages : en
Pages : 53

Book Description
While promising technological advances are under way to develop new health products for the fight against several poverty-related diseases, considerable gaps exist in most disease areas. During the 2023 WHO-PDP forum, PDPs, their funders and WHO deliberated on how to best close the gap for missing health technologies as well as how to build sustainable R&D systems in low- and middle income countries. Furthermore, WHO presented new initiatives and processes related to the work of PDPs and gathered feedback on the potential future role of WHO’s Science Division in the PDPs space.

Evidence generation for development of health products

Evidence generation for development of health products PDF Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240084290
Category : Medical
Languages : en
Pages : 40

Book Description
This document describes the main elements that World Health Organization (WHO) technical departments should elaborate on when providing guidance on evidence generation to research and development (R&D) specialists who are developing health products to address critical unmet needs in public health. While WHO’s TPPs, preferred product characteristics (PPCs) and target regimen profiles (TRPs) provide high-level information on the desired characteristics of the product, the target population, and the key endpoints for safety and efficacy evaluation, more detailed guidance is needed to enable the development of suitable trial/study designs aimed at producing relevant evidence for WHO’s normative products such as guidelines. The objective of the Guidance for evidence generation (GEG) process is to produce a guidance document on how best to perform studies for the development of novel products (diagnostics, drugs, vaccines, vector control) and thus how to enable the generation of robust data and evidence to inform a WHO evidence review process.

WHO meeting on preferred product characteristics for monoclonal antibodies for malaria prevention

WHO meeting on preferred product characteristics for monoclonal antibodies for malaria prevention PDF Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240060405
Category : Medical
Languages : en
Pages : 16

Book Description


WHO working group on late-stage development for malaria vaccines to reduce disease burden

WHO working group on late-stage development for malaria vaccines to reduce disease burden PDF Author:
Publisher: World Health Organization
ISBN: 9240048278
Category : Medical
Languages : en
Pages : 20

Book Description


WHO technical consultation on preferred product characteristics for drugs used in malaria chemoprevention

WHO technical consultation on preferred product characteristics for drugs used in malaria chemoprevention PDF Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240059016
Category : Medical
Languages : en
Pages : 22

Book Description


WHO Recommendations for Prevention and Treatment of Maternal Peripartum Infections

WHO Recommendations for Prevention and Treatment of Maternal Peripartum Infections PDF Author: World Health Organization
Publisher: World Health Organization
ISBN: 924154936X
Category : Medical
Languages : en
Pages : 80

Book Description
The goal of the present guideline is to consolidate guidance for effective interventions that are needed to reduce the global burden of maternal infections and its complications around the time of childbirth. This forms part of WHO's efforts towards improving the quality of care for leading causes of maternal death especially those clustered around the time of childbirth in the post-MDG era. Specifically it presents evidence-based recommendations on interventions for preventing and treating genital tract infections during labour childbirth or puerperium with the aim of improving outcomes for both mothers and newborns. The primary audience for this guideline is health professionals who are responsible for developing national and local health protocols and policies as well as managers of maternal and child health programmes and policy-makers in all settings. The guideline will also be useful to those directly providing care to pregnant women including obstetricians midwives nurses and general practitioners. The information in this guideline will be useful for developing job aids and tools for both pre- and inservice training of health workers to enhance their delivery of care to prevent and treat maternal peripartum infections.

Ranking Vaccines

Ranking Vaccines PDF Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309255252
Category : Medical
Languages : en
Pages : 188

Book Description
As a number of diseases emerge or reemerge thus stimulating new vaccine development opportunities to help prevent those diseases, it can be especially difficult for decision makers to know where to invest their limited resources. Therefore, it is increasingly important for decision makers to have the tools that can assist and inform their vaccine prioritization efforts. In this first phase report, the IOM offers a framework and proof of concept to account for various factors influencing vaccine prioritization-demographic, economic, health, scientific, business, programmatic, social, policy factors and public concerns. Ranking Vaccines: A Prioritization Framework describes a decision-support model and the blueprint of a software-called Strategic Multi-Attribute Ranking Tool for Vaccines or SMART Vaccines. SMART Vaccines should be of help to decision makers. SMART Vaccines Beta is not available for public use, but SMART Vaccines 1.0 is expected to be released at the end of the second phase of this study, when it will be fully operational and capable of guiding discussions about prioritizing the development and introduction of new vaccines.